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Atrial fibrillation (AF) is associated with a ≈5-fold increased risk of ischemic stroke,1 and stroke prevention 
is a major priority in the clinical management of AF. When 
compared with control/placebo, oral anticoagulation (OAC) 
therapy reduces the risk of stroke by 64% and the risk of death 
by 26%.2 Hence, current guidelines recommend OAC for 
stroke prevention of AF patients unless they are deemed to be 
at low risk of stroke.3–6 Given that OAC also increases bleed-
ing risk (which can be fatal), OAC therapy should be decided 
on the basis of the expected net clinical benefit of OAC ther-
apy. Therefore, stroke risk stratification is a critical step, and 
an annual stroke risk of 1% to 2% is considered as the thresh-





-VASc score (congestive heart failure, hyper-
tension, age ≥75 [doubled], diabetes mellitus, prior stroke 
or transient ischemic attack [doubled], vascular disease, age 
65–74, female)9 is now used in most guidelines for stroke 
prevention in AF, with OAC being generally recommended 




-VASc stroke score (congestive heart failure, hypertension, age ≥75 (doubled), 
diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65–74, female) is used in 
most guidelines for risk stratification in atrial fibrillation (AF), but most data for this score have been derived in Western 
populations. Ethnic differences in stroke risk may be present. Our objective was to investigate risk factors for stroke in 




-VASc score in an Asian AF population from Korea.
Methods—A total of 5855 oral anticoagulant–naive nonvalvular AF patients aged ≥20 years were enrolled from Korea 
National Health Insurance Service Sample cohort from 2002 to 2008 and were followed up until December 2013.









-VASc ≥2). Incidence rates 









-VASc risk factors and ischemic stroke were 
observed; however, the significance of vascular disease or diabetes mellitus was attenuated after multivariate adjustment, 
and female sex (hazard ratio, 0.73; 95% confidence interval, 0.64–0.84) had a lower risk of ischemic stroke than males. 
Patients who were categorized as low risk consistently had an event rate <1% per year.




-VASc score in Asians is comparable with that in Western populations. 
The score shows good performance in defining the truly-low-risk AF patients for stroke/thromboembolism.   (Stroke. 
2017;48:1524-1530. DOI: 10.1161/STROKEAHA.117.016926.)
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-VASc stroke risk factors.3–6 However, these 
guideline recommendations were derived from the assump-
tion that each score corresponds to fixed stroke rates, and most 




-VASc score were derived and validated 





VASc score to Asian populations has been debated because 
the annual stroke risk of some cohorts in Asian populations 
seems to vary from that reported from Western popula-
tions.11–15 Ethnic differences may also be evident, with higher 
event rates in Chinese cohorts15 compared with (for example) 
Japanese cohorts.16
Using a nationwide cohort database, our objective was to 





-VASc score in an Asian AF population from Korea.
Methods
National Health Insurance Service (NHIS) is the single insurer man-
aged by the Korean government, and the majority of Korean popu-
lation (97.1%) is mandatory subscribers, with the remaining 3% 
of the population being medical aid subjects. The database is open 
to researchers, whose study protocols are approved by the official 
review committee. Korean National Health Insurance Service - 
Sample Cohort (K-NHIS Sample Cohort) was created and released 
by NHIS in 2014 and contains 1 025 340 individuals representing 
the total Korean population from the beginning in 2002, amount-
ing to 2.2% of the entire population in the Korean National Health 
Insurance Service, and followed by 2013. The database contains 
patients’ sociodemographic information, their use of inpatient and 
outpatient services, pharmacy dispensing claims, and mortality data.
Study Population
A total of 7529 patients with AF who were aged ≥20 years were iden-
tified from Korea NHIS sample cohort database during the screening 
period from January 2002 to December 2008; 482 patients with val-
vular AF (mitral stenosis, any mechanical or bioprosthetic heart valve, 
or mitral valve repair) and 1192 patients receiving OACs at baseline 
were excluded. A final total of 5855 OAC-naive AF patients were 
enrolled in the study cohort and were followed up until December 
2013 (Figure 1). AF was identified with International Classification 
of Disease, Tenth Revision (ICD-10) codes; I48 (AF and atrial flutter), 
I48.0 (AF), and I48.1 (atrial flutter). To ensure accuracy, diagnosis 
was established based on 1 inpatient or 2 outpatient records of ICD-
10 codes in the database.17,18
To evaluate the accuracy of our definition of AF, we conducted a 
validation study in two hospitals with 628 randomly chosen patients 
with the ICD-10 code I48. Their ECGs were reviewed by 2 physi-
cians (Daehoon Kim and Junbeom Park). The patients were ascer-
tained to have AF if it was documented by ECG examinations. The 
positive predictive value was found to be 94.1%.
Baseline Comorbidities and End Points
Baseline comorbidities were evaluated during the 7-year screen-
ing period (January 2002 to December 2008) and identified from 
the medical claims according to the ICD-10 codes and prescription 
codes, and all comorbidities were established based on 1 inpatient 
or 2 or more outpatient records of ICD-10 codes in the database, 
which was similar to previous studies with NHIS sample cohort.19,20 
Hypertension, diabetes mellitus, chronic obstructive pulmonary dis-
ease, heart failure, end-stage renal disease, peripheral arterial disease, 
a history of myocardial infarction, and a history of stroke and tran-




-VASc score for 
each subject was estimated at the end of the screening period. The use 
of aspirin was also assessed at the start of the follow-up period, and 
only prescriptions >3 months were counted. To avoid the underesti-
mation of aspirin utilization because of over-the-counter purchase in 
the study population, we additionally analyzed the over-the-counter 
aspirin purchase data during the 5-year follow-up period. Definitions 
of comorbidities are presented in Table I in the online-only Data 
Supplement.
The primary end point was incident ischemic stroke (including 
ischemic stroke–related death) during the 5-year follow-up period 
(from January 2009 to December 2013). Any diagnosis of ischemic 
stroke with concomitant brain-imaging studies, including computed 
tomography or magnetic resonance imaging was defined as incident 
ischemic stroke. The secondary end point was the composite of pri-
mary end point and systemic embolism events (the composite throm-
boembolism end point), which was defined as having ICD-10 codes 
of atrial embolism (ICD-10: I74) or renal infarction (ICD-10: N280) 
as inpatient records. The accuracy of the diagnosis of an ischemic 
stroke in the NHIS claim data was previously validated.21
Statistical Analysis
Descriptive statistics were used to characterize baseline characteristics 




-VASc score. Continuous 
variables were expressed as the mean±SD, and categorical variables 
were reported as frequencies (percentage). The incidence rates of end 




-VASc score are presented as 100 
person-years and adjusted for exposure to aspirin treatment assuming 
that aspirin provides a 19% reduction in TE risk,2 to give an indication 
Figure 1. Flowchart of study cohort 
enrollment. AF indicates atrial fibrillation; 
and NHIS, National Health Insurance 
Service.
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of untreated rate. To provide perspective, we also show event rates 




-VASc score in the non-AF population 
from this data set. The cumulative incidence of AF and differences 




-VASc score were displayed and estimated 
by the Kaplan–Meier analysis using the log-rank test. To explore 
determinants for the risk of stroke, Cox proportional-hazards regres-
sion analysis was used to investigate the association between the 
comorbidities and the incidence of ischemic stroke or the composite 
thromboembolism end point. Factors associated with outcome after 
age and sex adjustment were used in a conditional forward Cox regres-
sion analysis. The threshold for entry was 0.05 and for removal was 
0.10. Remaining factors significantly associated with outcomes were 
retained for the final model. Interdependent covariables were not used 
simultaneously in any of the analyses. The patients were censored at 
the date when the ischemic stroke or the composite end point events 
occurred, at the date of their death, at the date of OAC initiation during 
follow-up period, or at end of follow-up.
To quantify the predictive value for ischemic stroke and the compos-
ite thromboembolism end point, we calculated the C statistics, which 
quantifies discriminant ability and is a measure of the area under the 
receiver–operator characteristic curve, and tested the hypothesis that 
these schemes performed significantly better than chance (indicated 
by a C statistic ≥0.5). The odds ratio for the increased relative risk of 
the absence of ischemic stroke was assessed by logistic regression 
analysis. All tests were 2-tailed, with P<0.05 considered significant. 
Statistical analysis was performed using the Statistical Package for 
the Social Sciences (SPSS 23.0; SPSS, Inc, Chicago, IL).
Results
This study included 5855 OAC-naive nonvalvular AF patients 
(mean age: 43.9±11.5 years; female 48.4%) who had diag-
nosed AF during the 6-year screening period. Patients were 




-VASc scores as low-risk (0 
or 1 point [in female]), intermediate-risk (1 point in male), 
and high-risk (≥2 points) groups, respectively. Patients’ dis-





-VASc scores are listed in Table 1. The proportion 
of patients aged ≥75 years was 26.7% in total population. 
Hypertension was the most prevalent comorbidity (75.5%), 
followed by heart failure (31.9%), vascular disease (20.6%), 
and diabetes mellitus (19.9%). Baseline characteristics of 2 





VASc score was derived9,22 are also listed in Table 1, for illus-
trative purposes.
Risk of Stroke
During the mean follow-up period of 50.6±17.6 months, 
819 of 5855 patients (14.0%) experienced incident ischemic 
stroke. The incidence rates (per 100 person-years) of ischemic 
stroke or the composite thromboembolism end point show a 




-VASc score (Table 2; 
Figure 2). The incidence rates (per 100 person-years) of isch-
emic stroke were 3.32 in the total study population, being 
0.23 in low-risk, 1.04 in intermediate-risk, and 4.59 in high-
risk patients. The incidence rates of ischemic stroke/systemic 





-VASc score are also listed in Table 2, for illustra-
tive purposes.





VASc score (ie, score 0 in males or 1 in females) consistently 
Table 1. Patient Baseline Characteristics





























Age, y 44±12 53±11 69±12 64±15 66±14 N/A
  <65 0 (0) 0 (0) 1561 (35.1) 2594 (44.3) N/A 15 130 (20.5)
  65–74 0 (0) 76 (13.8) 1624 (36.5) 1700 (29.0) N/A 14 544 (19.8)
  >75 860 (100) 474 (86.2) 1260 (28.3) 1561 (26.7) 309 (28.5) 43 864 (59.7)





-VASc score 0.52±0.50 1.00 4.09±1.69 3.28±2.08 N/A N/A
History of TIA/ischemic stroke 0 (0) 0 (0) 1433 (32.2) 1433 (24.5) 97 (9.1) 13 368 (18.2)
Atherosclerotic disease
  Myocardial infarction 0 (0) 8 (1.5) 756 (17.0) 764 (13.0) N/A N/A
  Peripheral arterial disease 0 (0) 7 (1.3) 604 (13.6) 611 (10.4) 62 (5.8) N/A
  Vascular disease 0 (0) 15 (2.7) 1191 (26.8) 1206 (20.6) N/A 12 873 (17.5)
Heart failure 0 (0) 17 (3.1) 1852 (41.7) 1869 (31.9) 253 (23.5) 13 126 (17.9)
Hypertension 0 (0) 405 (73.6) 4017 (90.4) 4422 (75.5) 729 (67.3) 25 060 (34.1)
Diabetes mellitus 0 (0) 37 (6.7) 1131 (25.4) 1168 (19.9) 187 (17.3) 6496 (8.8)
ESRD 2 (0.2) 5 (0.9) 82 (1.8) 89 (1.5) N/A N/A
COPD 38 (4.4) 26 (4.7) 609 (13.7) 673 (11.5) N/A N/A
Aspirin use 86 (10.0) 225 (40.9) 2325 (52.3) 2636 (45.0) 802 (74.0) 25 503 (34.7)
Values are expressed in n (%) or mean±SD. Vascular disease is previous myocardial infarction, peripheral arterial disease, or aortic plaque. COPD indicates chronic 
obstructive pulmonary disease; ESRD, end-stage renal disease; N/A, not available; NHIS, National Health Insurance Service; and TIA, transient ischemic attack.
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had an event rate <1% per year. The proportion of patients who 
remained in low risk gradually decreased from 14.7% at base-
line to 11.4% at the end of follow-up (or within a year before 
stroke), and there were 6 thromboembolic events in these 
truly-low-risk patients during the entire follow-up period of 5 
years (rate, 0.18 per 100 person-years; 95% confidence inter-





score was predictive of the absence of ischemic stroke dur-






-VASc score in this cohort was 3.28 (± 




-VASc score for 
stroke was good, as reflected by C indexes for ischemic stroke 
at 1 year and 5 years of 0.719 (95% CI, 0.71–0.73; P<0.001) 
and 0.714 (95% CI, 0.70–0.73; P<0.001), respectively.
Comparison With the Non-AF Population
The overall risk of stroke and systemic embolism in OAC-
naive AF patients was increased ≈3-fold compared with age- 
and sex-matched non-AF subjects. Table II in the online-only 





-VASc score, where AF patients had generally 
higher event rates compared with non-AF subjects. In the low-




-VASc 0 in males or 1 in females), the 
incidence per 100 person-years of stroke and systemic embo-
lism was similar to that seen in the non-AF population (0.26 
versus 0.23, respectively; Figure I in the online-only Data 
Supplement).
Risk Factors for Ischemic Stroke and the 
Composite Thromboembolism End Point
All risk factors, except female sex (hazard ratio [HR], 0.94; 





system showed significant associations with incident ischemic 
stroke on univariate analysis (Table 3). These associations with 
ischemic stroke events were greatest for age ≥75 years (HR, 
4.70; 95% CI, 3.32–4.37), history of stroke or transient isch-
emic attack (HR, 3.81; 95% CI, 3.32–4.37), end-stage renal 
disease (HR, 2.36; 95% CI, 1.56–3.57), and chronic obstruc-
tive pulmonary disease (HR, 1.72; 95% CI, 1.43–2.07).
On multivariable analysis, the significance of vascular dis-
ease (HR, 0.98; 95% CI, 0.84–1.15) or diabetes mellitus (95% 
CI, 1.13; 95% CI, 0.96–1.32) were attenuated after multivari-
ate adjustment, and female sex (HR, 0.75; 95% CI, 0.63–0.86) 
had a lower risk of ischemic stroke than males. The risk fac-
tors with significant associations were virtually the same 
irrespective of whether the end point was ischemic stroke or 
composite thromboembolism event.
Discussion
In this nationwide study using a large real-world cohort of 





VASc score shows good performance in the South Korean 
Table 2. Ischemic Stroke or the Composite Thromboembolism End Point per 100 Person-Years at Risk in Relation to CHA2DS2-VASc 







Korea NHIS Cohort Database (n=5855)  























Aspirin* Adjusted for Aspirin Unadjusted
0 (male) or 
1 (female)
860 0.23 0.26 0.26 0.29 0 0 0.69
1 (male) 550 1.04 1.18 1.20 1.35 1 0.7 1.51
2 975 1.91 2.21 2.04 2.35 2 1.9 3.01
3 911 2.54 2.88 2.67 3.04 3 4.7 4.41
4 836 4.72 5.34 5.10 5.76 4 2.3 6.69
5 770 5.79 6.54 5.98 6.76 5 3.9 10.42
6 513 8.36 9.50 8.61 9.77 6 4.5 12.85
≥7 440 8.82 9.97 9.03 10.21 ≥7 11.4 14.0
Total 5855 3.32 3.79 3.49 3.98 Total 2.3 5.29
NHIS indicates National Health Insurance Service.
*Adjustment made for exposure to aspirin treatment, assuming that aspirin provides a 19% reduction in thromboembolism risk, to give an indication of untreated rates.
Figure 2. The rate of ischemic stroke among patients with 
CHA2DS2-VASc scores of 0 to ≥7.
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population, particularly in defining the truly-low-risk AF 





-VASc–scoring system showed significant associa-
tions with ischemic stroke and the composite thromboembo-
lism end point, although female sex was not an independent 
risk factor for ischemic stroke or the composite end point after 
multivariate adjustment.
Discrepancies in Reported Stroke Rates
Several studies have demonstrated that the net clinical benefit 
of OAC is evident in AF patients with one or more stroke risk 
factors.23,24 Various guidelines recommend OAC use based on 










VASc point score stratum-specific stroke rates, reflecting dif-
ferent study settings, population cohorts, study methodology, 
or ethnic groups.25,26 Indeed, significant differences in reported 
event rates are evident in Asian studies, with higher event rates 
in Chinese cohorts.16 One US study suggested that African-





-VASc score,27 whereas Chao et al15 proposed 




-VASc score for Asians, with 
one point given for the age 50 to 64 years criteria.
Hence, additional studies are clearly needed to carefully 
define stroke rates in different ethnic groups. In this study, we 
have now demonstrated for the first time in a large Korean 





point score stratum–specific stroke rates compared with that 
seen in several Western cohorts cited in guidelines.22,28
Also, AF patients had generally higher event rates for each 




-VASc score compared with non-AF 





VASc 0 in males or 1 in females), the incidence per 100 per-
son-years of stroke and systemic embolism in AF patients was 
low and similar to rates seen in the non-AF population.
Defining the Truly-Low-Risk Patients
The suggested threshold of annual ischemic stroke risk for a 
favorable net clinical benefit from OAC for patients with AF 
is between 1% and 2%.7 The introduction of non–vitamin K 
antagonist OACs with improved efficacy and safety compared 
with warfarin has lowered the threshold for OAC therapy for 
AF patients from an annual stroke rate of 1.7% with vitamin 
K antagonists to 0.9% with non–vitamin K antagonist OACs.7 
Indeed, the 1.7% per year annual risk treatment threshold with 
warfarin may even be lower with good-quality anticoagulation 
control, as reflected by a time in therapeutic range >70%.29 
Therefore, the focus has now shifted away from predicting 
high-risk patients toward identifying patients with a truly 
low risk of ischemic stroke in whom OAC has no net clinical 
benefit.30
In this study, the incidence rates (per 100 person-years) of 















-VASc ≥2). Although some recent studies 
have shown higher reported stroke rates in Asian populations 
than those of other cohort studies in Western populations,11,31,32 
Table 3. Associations Between Baseline Factors and Ischemic Stroke and the Composite Thromboembolism End Point in Patients 
Without Anticoagulant Treatment







HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age, y
  <65 161/2594 Ref … Ref … 173/2594 Ref … Ref …
  65–74 320/1700 3.44 2.84–4.16 2.11 1.73–2.58 334/1700 3.34 2.78–4.02 2.10 1.73–2.55
  >75 338/1561 4.70 3.90–5.68 3.11 2.51–3.85 352/1561 4.55 3.79–5.47 3.11 2.52–3.82
Women 385/2835 0.94 0.82–1.07 0.75 0.63–0.86 398/2835 0.91 0.80–1.04 0.73 0.64–0.84
Ischemic stroke/TIA 411/1433 3.81 3.32–4.37 2.58 2.23–2.97 420/1433 3.61 3.16–4.13 2.44 2.12–2.80
  Atherosclerotic disease           
  Myocardial infarction 139/764 1.49 1.24–1.79 0.97 0.81–1.17 143/764 1.46 1.22–1.75 0.95 0.79–1.14
  Peripheral arterial disease 113/611 1.45 1.19–1.76 0.95 0.78–1.17 119/611 1.46 1.20–1.77 0.96 0.79–1.17
Vascular disease 221/1206 1.54 1.32–1.80 0.98 0.84–1.15 231/1206 1.54 1.32–1.79 0.95 0.84–1.14
Heart failure 380/1869 2.16 1.88–2.48 1.23 1.06–1.42 403/1869 2.21 1.93–2.52 1.26 1.09–1.45
Hypertension 750/4422 4.04 3.16–5.17 1.85 1.43–2.40 781/4422 3.72 2.95–4.70 1.69 1.32–2.15
Diabetes mellitus 216/1168 1.53 1.31–1.79 1.13 0.96–1.32 228/1168 1.55 1.33–1.80 1.14 0.98–1.33
ESRD 23/89 2.36 1.56–3.57 2.03 1.33–3.09 30/89 3.12 2.17–4.49 2.73 1.88–3.97
COPD 134/673 1.72 1.43–2.07 1.13 0.94–1.37 143/673 1.76 1.47–2.10 1.16 0.97–1.40
Aspirin use 505/2636 1.93 1.68–2.23 1.30 1.12–1.50 526/2636 1.90 1.66–2.18 1.28 1.11–1.47
CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; HR, hazard ratio; and TIA, transient ischemic attack.











-VASc score seems to have a good performance 
in defining the truly-low-risk AF patient for stroke in the 





-VASc score category for predicting the 
absence of ischemic stroke.
Stroke Risk Factors
Several cohort studies have shown that female sex is a risk fac-
tor for stroke, albeit with an age dependency to this risk.33–37 
Several Asian cohort studies from Hong Kong,11 China,12 
Taiwan,38 and Japan13 have suggested that female sex was not 
an independent risk factor for ischemic stroke, again suggesting 
some potential ethnic differences in the risk of stroke between 
Asian and non-Asian populations. Consistent with previous 
Asian studies, female sex was not a risk factor for stroke in our 
cohort and instead had a lower stroke risk of ischemic stroke 
than males. Beyond the biological difference between males 
and females, other sex differences in lifestyle patterns, social 
responsibility, and behaviors can make a different impact on 
the sex differences according to ethnicity. However, we are not 
able to identify these complicated factors within our cohort 
database. Further prospective studies are needed to evaluate this 
sex effect on stroke risk in AF patients. Other risk factors in 
our population such as older age, history of stroke or transient 
ischemic attack, heart failure, and hypertension remained inde-
pendent stroke risk factors, consistent with Western cohorts.
Limitations
To our knowledge, this is the first population-based investiga-
tion in the Korean population to assess the risk of ischemic 
stroke in OAC-naive AF patients. Our study should be inter-
preted in the context of the following limitations. First, baseline 
AF diagnosis and estimation of incidence of ischemic stroke 
or systemic embolism were on diagnostic codes registered by 
the physicians; therefore, the diagnosis of AF and ischemic 
stroke could be inaccurate although the method for the diag-
nosis has been validated in previous studies, and our internal 
validation found a high correlation with actual AF diagnosis. 
Second, patients who received aspirin were enrolled in the pres-
ent study; therefore, the stroke rate could be slightly affected by 
aspirin use, despite some adjustment for aspirin use in analyses.
Conclusions




-VASc score in Asians is com-
parable with that seen in Western populations. The score 
shows good performance in defining the truly-low-risk AF 
patients for stroke/TE.
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Supplementary Table 1. Definitions and ICD-10 codes used for defining the comorbidities 
Comorbidities Definitions ICD-10 codes or conditions 
Heart failure Defined from diagnosis* ICD10: I11.0, I50, I97.1 
Hypertension Defined from diagnosis* ICD10: I10, I11, I12, I13, I15 
Diabetes mellitus 
Defined from diagnosis* plus 
treatment 
ICD10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral 
antidiabetics and insulin 
Ischemic stroke Defined from diagnosis* ICD10: I63, I64 
TIA Defined from diagnosis* ICD10:  G45 
Previous MI Defined from diagnosis* I21, I22, I25.2 
Peripheral arterial 
disease 
Defined from diagnosis* 
ICD10: I70.0, I70.1, I70.2, I70.8, 
I70.9 
*To ensure accuracy, comorbidities were established based on one inpatient or two outpatient 
records of ICD-10 codes in the database. 
  
  
Supplementary Table II. Ischemic stroke, systemic embolism, or the composite thromboembolism endpoint /100 person-years at risk in 
relation to CHA2DS2-VASc scores in 5,855 OAC naïve AF population and age/sex matched non-AF population. 
CHA2DS2-VASc 
score 
OAC naïve AF Korean population 
(n=5,855) 
*Age and sex matched 












0 (male) or 1 
(female) 
0.23 0.02 0.26  0.23 0.02 0.23 
1 (male) 1.04 0.15 1.18  0.93 0.07 0.97  
2 1.91 0.17 2.21  1.24 0.10 1.30 
3 2.54 0.19 2.88  1.82 0.12 1.94 
4 4.72 0.42 5.34  2.51 0.20 2.74 
5 5.79 0.35 6.54  3.53 0.22 3.91 
6 8.36 0.60 9.50  4.25 0.25 4.70 
7 or more 8.82 0.61 9.97  5.12 0.40 5.67 
Total 3.32 0.27 3.79  1.32 0.10 1.39 
*Age and sex matched with Propensity-score matching with propensity scores estimated using a non-parsimonious multiple logistic 
regression model between OAC naïve AF group and non-AF group (1:20 matching). The matching procedure was performed using R 
packages, including Matchit, RItools, and CEM (Ho DE et al. Matching as nonparametric preprocessing for reducing model dependence in 
parametric causal inference. Political Analysis 2007; 15: 199-236.). 
  
Supplementary Figure I. Incidence rates of ischemic stroke/systemic embolism according to each CHA2DS2-VASc scores (A) and risk 
categories as stratified by low (score 0 or 1 in female), intermediate (1 in male), and high risk (≥2) (B). 
 
